JLJosephine H. Li

Josephine H. Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Josephine H. Li has a total of 787 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Common Genetic Variants Near SLC2A2 and Glycemic Response to Glimepiride in the GRADE Comparative Effectiveness Clinical Trial

    by Josephine H. Li, Lukasz Szczerbinski, Mark Tripputi, Haiyin Liu, Stella Nam, Endrina Mujica, Anastasia Emmanouilidou, Thinley Y. Wangden, Anna Citko-Rojewska, Paulina Konopka, et al.

    OBJECTIVE: Optimizing second-line therapy for type 2 diabetes remains challenging because of interindividual variability in response. Current treatment selection does not consider personal genetic profiles. To address this gap, we conducted a pharmacogenomic genome-wide association study (GWAS) in a randomized comparative effectiveness trial to identify genetic predictors of glycemic response to insulin glargine, glimepiride, liraglutide, and sitagliptin when added to metformin. RESEARCH DESIGN AND METHODS: In the Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study (GRADE), we performed a GWAS for the time to reach primary (glycated hemoglobin [HbA1c] ≥7%) and secondary (HbA1c >7.5%) metabolic failure. We conducted replication in independent cohorts, performed fine mapping of the top variants near SLC2A2, evaluated them for physiologic impact using oral glucose tolerance testing (OGTT) and response to acute glipizide challenge, and characterized glycemic response to glimepiride in an slc2a2-mutated zebrafish model. RESULTS: rs2129019 in SLC2A2 encoding GLUT2 was enriched in African/African American participants and conferred a 38% increased risk of metabolic failure per A allele on glimepiride (P = 1.55 × 10−8). Carriers had impaired β-cell function, evidenced by a lower C-peptide index during OGTT, and diminished glucose-lowering response to acute sulfonylurea challenge. Genetic manipulation in zebrafish confirmed that slc2a2 disruption attenuated the glucose-lowering effect of glimepiride. CONCLUSIONS: Genetic variation influences glycemic response to glucose-lowering medications, with SLC2A2 emerging as a genetic factor that modulates sulfonylurea response. These findings warrant further study to evaluate whether low-response allele carriers would benefit from alternative glucose-lowering therapies to advance precision diabetes care.

  • Open Access

    Disentangling Sex Differences in Sulfonylurea Drug Response With Genome‐Wide Association Studies in Individuals With Type 2 Diabetes

    by Joseph H. Breeyear, John S. House, Mark Kvale, Stella Nam, Farida S. Akhtari, Hetal S. Shah, Monique M. Hedderson, Kathleen M. Giacomini, Josyf C. Mychaleckyj, Alessandro Doria, et al.

    Sulfonylureas are a cornerstone of type 2 diabetes therapy despite interindividual variability in response. Despite well‐documented sex‐based differences, pharmacogenomic and genome‐wide association studies (GWAS) have largely overlooked sex as a biological variable. We conducted the first sex‐stratified GWAS of hemoglobin A1c (HbA1c) response to sulfonylureas in Action to Control Cardiovascular Risk in Diabetes (ACCORD) clinical trial participants ( N = 871). Variants meeting genome‐wide ( P < 5.0 × 10 –8 ) and suggestive ( P < 5.0 × 10 –6 ) significance were assessed for replication in the Pharmacogenomics of Metformin (PMET1) cohort. Replicated variants were further analyzed in the Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans (SUGAR‐MGH) cohort to assess acute insulin and glucose responses to a single glipizide dose. Genome‐wide significant loci with sex‐specific effects were identified: KAZN , KIF2B , SLC39A10 , and SPINK5 (combined‐sex); CRACR2A , KCNK2 , and TENM2 (male‐only); and NACPH2 (female‐only). Two suggestive variants in the TMEM64 / NECAB1 locus, associated with reduced HbA1c response to sulfonylureas in the male‐only ACCORD analysis, were directly replicated in the PMET1 male‐only cohort. In SUGAR‐MGH, one replicated variant (rs6471250‐C) was significantly associated with reduced peak insulin in males ( P = 0.035) but not females ( P = 0.40), demonstrating sex‐specific functional effects. This study identified statistically supported and biologically plausible loci with prior evidence linking nearby genes to pathways relevant to sulfonylurea action, including insulin secretion, insulin regulation/sensitivity, calcium signaling, potassium‐channel biology, and glucose transport. The findings highlight sex‐specific differences in sulfonylurea response, providing mechanistic insights and underscoring the importance of sex‐specific precision medicine. Identification of genetic variants influencing sex‐specific response could inform dosing to optimize sulfonylureas.

  • Open Access

    Genetic and Clinical Factors Associated With Metformin Plasma Concentrations Following an Acute Metformin Challenge

    by Bryan Kuo, Stella Nam, Varinderpal Kaur, Farah Jones, Josep M Mercader, Sook Wah Yee, Jose C Florez, Shylaja Srinivasan, Josephine H Li

    The glycemic response to metformin is highly variable, yet the genetic determinants of metformin pharmacokinetics remain poorly characterized. In the Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans (SUGAR-MGH), an ancestrally diverse cohort, we evaluated clinical and genetic factors associated with plasma metformin concentrations. Plasma metformin concentrations were measured in 745 participants who completed a standardized acute metformin challenge in SUGAR-MGH. Higher metformin concentrations were associated with older age (β=2.5 ng/mL per year, p = 0.02), lower eGFR (β=-3.5 ng/mL per ml/min/1.73m2, p = 4.5 × 10−4), and lower BMI (β=-7.3 ng/mL per kg/m2, p = 1.3 × 10−4). African ancestry was associated with lower metformin concentrations compared to European ancestry (β=-72.6 ng/mL, p = 0.036). A genome-wide association study (GWAS) identified four African ancestry-specific genetic variants significantly associated with higher metformin concentrations (p < 5 × 10−8) as well as several suggestive loci near genes implicated in glucose metabolism, including USP36 and DGKB. Top variants associated with metformin concentration were not associated with glycemic response endpoints following the metformin challenge, including fasting glucose at Visit 2, change in HOMA-IR, and change in fasting insulin between visits. Previously reported metformin transporter variants showed no significant associations with metformin concentration. These findings represent the first GWAS of metformin plasma concentrations and provide a novel resource for future studies of metformin pharmacogenetics.


  • Open Access

    Urinary Iodine-to-Creatinine Ratio and Outcomes After Radioactive Iodine Ablation in Thyroid Cancer

    by Maria Vamvini, Ashna Grover, Josephine H Li, Zhiheng H He, James V Hennessey

    Context: Radioactive iodine ablation (RAIA) in differentiated thyroid cancer (DTC) requires elevated TSH levels, achieved through thyroid hormone withdrawal (THW) or recombinant human TSH (rhTSH). A low-iodine diet (LID) is recommended to enhance RAIA efficacy, but its impact on long-term outcomes remains uncertain. Objective: To determine whether pre-ablation urinary iodine concentrations predict disease outcomes after RAIA. Study design: Retrospective study of DTC patients treated with post-surgical RAIA at BIDMC from 2007-2020 Patients: Of 463 patients reviewed, 304 met inclusion criteria (THW:189; rhTSH:115). All completed a 2-week LID. Urinary iodine-to-creatinine ratio (UICR) was measured as a marker of iodine status. Main Outcome Measure(s): Disease recurrence at 12 months, defined by elevated thyroglobulin (Tg), abnormal neck ultrasound, or a positive whole-body scan. Associations between UICR and outcomes were evaluated using univariable and multivariable logistic regression. Results: Positive pre-treatment Tg (OR 6.13, 95% CI 1.90–19.83; p=0.002) and AJCC stage IV disease (OR 8.45, 95% CI 1.39–51.36; p=0.02) were independently associated with recurrence. Older age was associated with lower recurrence risk only in unadjusted models. UICR showed no association with outcomes. Although mean UICR was higher in the rhTSH group (p<0.0001), recurrence rates were similar between THW and rhTSH (p=0.3). Conclusions: Higher UICR in rhTSH-prepared patients did not translate into worse outcomes. Pre-treatment Tg and stage IV disease were the strongest predictors of recurrence, whereas iodine status was not. These findings suggest that strict iodine depletion at the level achieved here, reflected by UICR, may not determine RAIA efficacy in DTC.

  • Open Access

    Identification of a genetic risk factor for metformin-induced vitamin B12 deficiency

    by Faye D. Baldwin, Khaled F. Bedair, Andrea L. Jorgensen, Lewis Green, Innocent G. Asiimwe, Colin N. A. Palmer, Archie Campbell, Caroline Hayward, Qing Pan, Shiyu Shu, et al.

    Aims/hypothesis: Metformin, a mainstay of treatment for type 2 diabetes, can cause vitamin B 12 deficiency. Clinical risk factors have been identified but genetic factors remain undiscovered. Our objective was to identify and validate genetic predisposing factors and establish clinical utility. Methods: Individuals with metformin-induced vitamin B 12 deficiency ( n =487) and metformin-tolerant control individuals ( n =6686) were identified in UK Biobank. Genome-wide association analysis was undertaken using logistic regression. Replication was undertaken in three cohorts: a Scottish cohort; the Diabetes Prevention Program Outcomes Study (DPPOS); and a separate cohort from Liverpool. In the Liverpool cohort, plasma metformin levels were also measured. Results: Analysis identified a genome-wide significant non-synonymous SNP in the cubilin gene ( CUBN, rs1801222/p.S253F) associated with metformin-induced vitamin B 12 deficiency (additive model; adjusted p =1.86×10 −10 ; OR 1.56 [95% CI 1.36, 1.79] for AG vs GG genotype; OR 2.43 [95% CI 1.85, 3.20] for AA vs GG genotype), which was replicated in both the Scottish and the DPPOS cohorts. Vitamin B 12 deficiency occurred in 0.84–1.20% of non-metformin-exposed individuals regardless of rs1801222 genotype. However, a large interaction with metformin use was observed, with vitamin B 12 deficiency occurring at 6.02% in GG, 7.96% in GA and 12.84% in AA genotype groups. When followed up from metformin initiation, 10% with the AA genotype were vitamin B 12 deficient by 11 years vs 21 years for 10% of the GG group. Conclusions/interpretation: The observed genetic association suggests that the rs180122 genotype should be considered a significant risk factor for metformin-induced vitamin B 12 deficiency. While clinical monitoring of serum vitamin B 12 levels in patients on metformin is inconsistently done, this finding highlights the potential clinical utility of targeted monitoring for certain subsets of individuals, including those genetically at high risk. Graphical


  • Open Access

    Expansion of a physician parental wellness programme at the Massachusetts General Hospital to improve physician well-being

    by Josephine H Li, Megan F Hoang, Lauren E Olson, Kerri Palamara, Erin E Sullivan, Laura E Dichtel

    Background: Physician parents experience challenges during their transition to parenthood and their return to work. We expanded a Parental Wellness Programme (PWP) to Department of Medicine faculty physicians and evaluated its impact on physician well-being. The programme supported new physician parents through peer mentorship and financial resources. Methods: Through internal marketing, expectant and new parent faculty were encouraged to self-enrol and were supported until 12 months following the child’s birth (up to an 18-month period). Participants enrolled between October 2021 and September 2022. The programme included a US$500 feeding/lactation reimbursement and pairing with a parental wellness advocate (PWA), a physician with parenting experience. Anonymised participant surveys were voluntary and conducted at programme entry, and at 6 months and 12 months following the child’s birth to assess return-to-work experience, lactation, burnout and programme impact. A final feedback survey was sent after all participants completed the programme. Results: The programme supported 67 participants (82% women). 53 participants responded to the baseline survey, of whom 85% were junior faculty/early career. At baseline, 85% of respondents planned to breastfeed; 88% at 12 months (n=25) reported breastfeeding. Participants indicated a desire for connection, support and resources at baseline; follow-up surveys confirmed that the programme provided these supports. By 12 months, 76% received individualised PWA support, 88% used the feeding/lactation reimbursement and 92% self-reported improved well-being on return to work. All respondents indicated they would recommend the programme to colleagues. Participant comments highlighted challenges with parental leave coverage, and time and space for lactation. Conclusions: We demonstrated the scalability of a novel PWP that successfully supported early career and junior faculty during a difficult transition period. Feedback indicated ongoing system-based challenges and a need for institutional culture change.

  • Open Access

    Common genetic variants near SLC2A2 and glycemic response to glimepiride in the GRADE comparative effectiveness clinical trial

    by Josephine H. Li, Lukasz Szczerbinski, Mark Tripputi, Haiyin Liu, Stella Nam, Endrina Mujica, Anastasia Emmanouilidou, Thinley Yidzin Wangden, Anna Citko-Rojewska, Paulina Konopka, et al.

    Optimizing second-line therapy for type 2 diabetes is challenging due to interindividual variability in response. We conducted a pharmacogenomic genome-wide association study (GWAS) in the Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness (GRADE) Study to identify genetic predictors of glycemic response to insulin glargine, glimepiride, liraglutide, and sitagliptin, when added to metformin in a diverse population. We identified 21 genome-wide significant loci associated with treatment response. rs1905505, a non-coding variant near SLC2A2 , the gene encoding the glucose transporter GLUT2, was enriched in Africans/African Americans and conferred a 36% increased risk of treatment failure on glimepiride ( p =4.83×10). Carriers had impaired β-cell function, evidenced by a lower C-peptide index during OGTT, and diminished glucose-lowering response to an acute sulfonylurea challenge. Genetic manipulation in zebrafish confirmed that slc2a2 disruption attenuates the glucose-lowering effect of glimepiride. In conclusion, genetic variation influences glycemic response to medications, with SLC2A2 emerging as a key determinant of sulfonylurea response. Clinical Trial registration number: NCT01794143

  • Top Cited Papers
    Open Access

    Association between plausible genetic factors and weight loss from GLP1-RA and bariatric surgery

    by Jakob German, Mattia Cordioli, Veronica Tozzo, Sarah Urbut, Kadri Arumäe, Roelof A. J. Smit, Jiwoo Lee, Josephine H. Li, Adrian Janucik, Yi Ding, et al.

    Obesity is a major public health challenge. Glucagon-like peptide-1 receptor agonists (GLP1-RA) and bariatric surgery (BS) are effective weight loss interventions; however, the genetic factors influencing treatment response remain largely unexplored. Moreover, most previous studies have focused on race and ethnicity rather than genetic ancestry. Here we analyzed 10,960 individuals from 9 multiancestry biobank studies across 6 countries to assess the impact of known genetic factors on weight loss. Between 6 and 12 months, GLP1-RA users had an average weight change of −3.93% or −6.00%, depending on the outcome definition, with modest ancestry-based differences. BS patients experienced −21.17% weight change between 6 and 48 months. We found no significant associations between GLP1-RA-induced weight loss and polygenic scores for body mass index or type 2 diabetes, nor with missense variants in GLP1R. A higher body mass index polygenic score was modestly linked to lower weight loss after BS (+0.7% per s.d., P = 1.24 × 10−4), but the effect attenuated in sensitivity analyses. Our findings suggest known genetic factors have limited impact on GLP1-RA effectiveness with respect to weight change and confirm treatment efficacy across ancestry groups.


  • Open Access

    Author Correction: Rare variant analyses in 51,256 type 2 diabetes cases and 370,487 controls reveal the pathogenicity spectrum of monogenic diabetes genes

    by Alicia Huerta-Chagoya, Philip Schroeder, Ravi Mandla, Jiang Li, Lowri Morris, Maheak Vora, Ahmed Alkanaq, Dorka Nagy, Lukasz Szczerbinski, Jesper G. S. Madsen, et al.


  • Open Access

    Towards Scalable Biomarker Discovery in Posttraumatic Stress Disorder: Triangulating Genomic and Phenotypic Evidence from a Health System Biobank

    by Younga Heather Lee, Yingzhe Zhang, Ana Lucia Espinosa Dice, Josephine H. Li, Justin D. Tubbs, Yen-Chen Anne Feng, Tian Ge, Adam X. Maihofer, Caroline M. Nievergelt, Jordan W. Smoller, et al.

    Importance: Biomarkers can potentially improve the diagnosis, monitoring, and treatment of posttraumatic stress disorder (PTSD). However, PTSD biomarkers that are scalable and easily integrated into real-world clinical settings have not been identified. Objective: To triangulate phenotypic and genomic evidence from a health system biobank with a goal of identifying scalable and clinically relevant biomarkers for PTSD. Design, setting, and participants: The analysis was conducted between June to November 2024 using genomic samples and laboratory test results recorded in the Mass General Brigham (MGB) Health System. The analysis included 23,743 European ancestry participants from the nested MGB Biobank study. Exposures: The first exposure was polygenic risk score (PRS) for PTSD, calculated using the largest available European ancestry genome-wide association study (GWAS), employing a Bayesian polygenic scoring method. The second exposure was a clinical diagnosis of PTSD, determined by the presence of two or more qualifying PTSD phecodes in the longitudinal electronic health records (EHR). Main outcomes and measures: The primary outcomes were the inverse normal quantile transformed, median lab values of 241 laboratory traits with non-zero h 2 SNP estimates. Results: Sixteen unique laboratory traits across the cardiometabolic, hematologic, hepatic, and immune systems were implicated in both genomic and phenotypic lab-wide association scans (LabWAS). Two-sample Mendelian randomization analyses provided evidence of potential unidirectional causal effects of PTSD liability on five laboratory traits. Conclusion and relevance: These findings demonstrate the potential of a triangulation approach to uncover scalable and clinically relevant biomarkers for PTSD. Key points: Question: Is genetic liability or diagnosis of PTSD associated with clinical laboratory measures? Findings: Among European ancestry participants in the MGB Biobank, we identified 16 unique laboratory traits in cardiometabolic, hematologic, hepatic, and immune systems that were both genetically and phenotypically associated with PTSD, with five markers demonstrating potential unidirectional causal effects of PTSD liability. Meaning: Our findings reveal associations between PTSD and laboratory markers across multiple physiological systems, with evidence suggesting possible unidirectional causal effects of PTSD liability on cardiometabolic, hematologic, and hepatic markers.